StockNews.AISignal intelligence
Absci Corporation · NASDAQ · Healthcare
Browse public ABSI signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Absci partners with Oracle and AMD for AI-driven drug discovery. New tech accelerates biologics design cycles and model training. Stock increases 10.50% to $2.63 following the announcement. Collaboration provides high-performance infrastructure for large-scale simulations.
View signal analysisABSI stock fell 13.7% to $3.03 in pre-market trading. The decline followed Absci Corporation's public offering announcement. Market reaction may indicate investor concerns about future performance. Intel's negative earnings report exacerbates market uncertainty. Wider market trends are mixed, impacting investor sentiment.
View signal analysisAbsci Corporation's shares fell 9.4% following earnings report. Quarterly loss of 25 cents per share missed expectations. Sales of $665,000 also missed analyst estimates of $1.778 million. This performance reflects unchanged results from the previous year. Broader market futures rose, contrasting with ABSI's decline.
View signal analysisNeedham initiates coverage on Absci Corporation (ABSI) with a Buy rating. ABSI focuses on drug development using AI/ML and synthetic biology. Collaboration with AMD enhances its AI drug discovery capabilities. The company aims for first-in-class therapies with partners after trials. Price target set at $9, indicating potential growth for ABSI.
View signal analysisAMD invests $20 million in Absci to enhance drug discovery capabilities. Absci's stock surged 54% following AMD's announcement of investment. The partnership aims to leverage AI for faster and cheaper drug development. Traditional drug discovery is costly, with 90% of candidates failing in trials.
View signal analysis